Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?

Cancers (Basel) · 2022 · PMC9562911 · PMID 36230785

Europe PMC DOI

hedged sentence

0.4900

closest p · 9.8× alpha

0.4900

boldest claim

The sentences

showed a trendp = 0.49not close (p > 0.1)

The study comparing the combination therapy of carboplatin and gemcitabine with gemcitabine monotherapy showed a trend toward longer overall survival (OS) (6.7 months vs. 4.8 months, p = 0.49) and progression free survival (PFS) (4.1 months vs. 3.0 months, p = 0.36) in the combination therapy group, although the results were not statistically significant [ 13 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.